Orforglipron (also known as Foundayo) is one of the most promising drugs in the GLP-1 space, notably as only the second oral GLP-1 option for obesity. Unlike injectable treatments, it does not require refrigeration and is easier to scale for widespread use. Dave highlights the ongoing questions that linger about the drugs approval as it relates to liver safety.
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Eli Lilly Just Revealed Something About The GLP-1 Market
SURVODUTIDE Phase 3 Data: Why Weight Loss Isn't The Whole Story
BPI STOPS TIRZEPATIDE Production, Second Major Pharmacy Out!
Retatrutide Could Change Everything… But Who Actually Gets It?
Free AI-powered recaps of On The Pen GLP-1 News and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.